Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

S. Gerritse; R. ter Heine; M. Labots; E. van den Hombergh; H. Dekker; D. Lehutová; M. Rudek; N. van Erp; H. Verheul

doi:10.1016/S0959-8049(20)31114-X

Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

S. Gerritse, R. ter Heine, M. Labots, E. van den Hombergh, H. Dekker, D. Lehutová, M. Rudek, N. van Erp, H. Verheul

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	S19
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)31114-X
Publication status	Published - 1 Oct 2020

Access to Document

10.1016/S0959-8049(20)31114-X

Cite this

Gerritse, S., ter Heine, R., Labots, M., van den Hombergh, E., Dekker, H., Lehutová, D., Rudek, M., van Erp, N., & Verheul, H. (2020). Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen. European Journal of Cancer, 138, S19. https://doi.org/10.1016/S0959-8049(20)31114-X

@article{0fceb139f4714ffe9caaec6404c8443a,

title = "Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen",

author = "S. Gerritse and {ter Heine}, R. and M. Labots and {van den Hombergh}, E. and H. Dekker and D. Lehutov{\'a} and M. Rudek and {van Erp}, N. and H. Verheul",

note = "Funding Information: Other Substantive Relationships: Receive grants from: Novartis, Astellas, AstraZeneca, Bristol-Meyers Squibb, Gilead, Ipsen, Janssen, Pfizer, and Roche. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(20)31114-X",

language = "English",

volume = "138",

pages = "S19",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

}

Gerritse, S, ter Heine, R, Labots, M, van den Hombergh, E, Dekker, H, Lehutová, D, Rudek, M, van Erp, N & Verheul, H 2020, 'Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen', European Journal of Cancer, vol. 138, pp. S19. https://doi.org/10.1016/S0959-8049(20)31114-X

TY - JOUR

T1 - Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

AU - Gerritse, S.

AU - ter Heine, R.

AU - Labots, M.

AU - van den Hombergh, E.

AU - Dekker, H.

AU - Lehutová, D.

AU - Rudek, M.

AU - van Erp, N.

AU - Verheul, H.

N1 - Funding Information: Other Substantive Relationships: Receive grants from: Novartis, Astellas, AstraZeneca, Bristol-Meyers Squibb, Gilead, Ipsen, Janssen, Pfizer, and Roche. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85093916257&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(20)31114-X

DO - 10.1016/S0959-8049(20)31114-X

M3 - Article

VL - 138

SP - S19

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

Access to Document

Other files and links

Cite this